RT Journal Article
SR Electronic
T1 Liquid Biopsy for Detection of Pancreaticobiliary Cancers in Suspected Patients by Functional Enrichment and Immunofluorescent Profiling of Circulating Tumor Cells and their Clusters
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.13.24302805
DO 10.1101/2024.02.13.24302805
A1 Gaya, Andrew
A1 Rohatgi, Nitesh
A1 Limaye, Sewanti
A1 Shreenivas, Aditya
A1 Ajami, Ramin
A1 Akolkar, Dadasaheb
A1 Datta, Vineet
A1 Srinivasan, Ajay
A1 Patil, Darshana
YR 2024
UL http://medrxiv.org/content/early/2024/02/15/2024.02.13.24302805.abstract
AB Background Circulating tumor cells (CTCs) have historically been used for prognostication in oncology. We evaluate performance of liquid biopsy CTC assay as a diagnostic tool in suspected pancreaticobiliary cancers. The assay utilises functional enrichment of CTCs followed by immunofluorescent profiling of organ specific markers.Methods Multicentric case control study was followed by a prospective observational study. Adult patients undergoing tissue sampling for suspected pancreaticobiliary cancer were included in the studies. Blood samples for TruBlood® CTC assay were drawn before tissue sampling. Patients with a prior cancer treatment or cancer history were excluded. CTCs and their clusters were harvested by a unique functional enrichment method which is label-free, size independent and non-mechanical. The CTCs then underwent immunofluorescent profiling for CA19.9, Maspin, EpCAM, CK and CD45, blinded to the tissue histopathological diagnosis. TruBlood® malignant or non-malignant predictions were compared with tissue diagnoses to establish the sensitivity and specificity.Results The case-control study evaluated 360 participants including 188 cases diagnosed with pancreaticobiliary cancer and 172 healthy individuals. A subsequent prospective observational study included 88 individuals with suspicion of pancreaticobiliary malignancy. The test had 95.9% overall sensitivity (95% CI: 86.0% - 99.5%) and 92.3% specificity (95% CI: 79.13% to 98.38%) to differentiate pancreaticobiliary cancers (PBC) (n = 49) from benign PB conditions (n = 39).Conclusions The high accuracy of the CTC based TruBlood test demonstrates its potential clinical application as a diagnostic tool to assist effective detection of pancreaticobiliary cancers when tissue sampling is unviable or inconclusive. A confirmational prospective interventional studiy in patients with suspicion of pancreaticobiliary malignancy including those with unavailability of tissue diagnosis is warranted.Competing Interest StatementAG, NR, AdS and RA declare no COI. SAL declares COI in the form of consulting role, advisory role, speakers bureau as well as stock and other ownership interests with entities and organizations not associated with the current study. DA, VD, AjS and DP are full time employees of the Study Sponsor.Funding StatementNo external funding was obtained for this study. The entire study was funded by the Study Sponsor (DCG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies with human participants were approved by an Ethics Committee of the study sponsor and / or the participating site. The Institutional Ethics Committee (IEC) of Datar Cancer Genetics (DCG, sponsor) gave ethical approval for the TRUEBLOOD and RESOLUTE studies. The CTC-based Cancer Detection and Diagnosis Study was approved by the site ECs including Health Point Hospital (site), Krishna Institute of Medical Sciences (site) as well as an independent EC, viz., Royal Pune Independent Ethics Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors%PercentAbAntibodiesADAdenocarcinomaCA19.9Cancer Antigen 19.9CAPCollege of American PhysiciansCD45Common Leucocyte AntigenCEACarcinoembryonic AntigenCEMCTC Enrichment MediumCIConfidence IntervalCKCytokeratinCLIAClinical Laboratory Improvement AmendmentsCTComputed TomographyCTCCirculating Tumor CellddPCRDroplet Digtal Polymerase Chain ReactionDCGDatar Cancer GeneticsECEthics CommitteeEpCAMEpithelial Cell Adhesion MoleculeERCPEndoscopic Retrograde CholangiopancreatographyEUSEndoscopic UltrasoundFNACFine Needle Aspiration CytologygDNAGenomic DNAHPEHistopathological examinationICCImmunocytochemistryIECInstitutional Ethics CommitteeIgGImmunoglobulin GLoBLimit of BlankLoDLimit of DetectionMRCPMagnetic Resonance CholangiopancreatographyMaspinMammalian serine proteinase inhibitorNGSNext Generation SequencingNETNeuroendocrine TumorsPBPancreaticobiliaryPBCPancreaticobiliary cancersRBCRed Blood CellsSTRShort Tandem RepeatSTROBEStrengthening the Reporting of Observational Studies in EpidemiologyUSGUltrasonographyUSPSTFUnited States Preventive Services Task ForceWBCWhite Blood Cells;